Claud Grigg

2.4k total citations · 2 hit papers
22 papers, 1.5k citations indexed

About

Claud Grigg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Claud Grigg has authored 22 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Claud Grigg's work include Cancer Immunotherapy and Biomarkers (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Urinary and Genital Oncology Studies (6 papers). Claud Grigg is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Urinary and Genital Oncology Studies (6 papers). Claud Grigg collaborates with scholars based in United States. Claud Grigg's co-authors include Naiyer A. Rizvi, Ruhong Zhou, Vladimir Makarov, Timothy A. Chan, Jeffrey K. Weber, David M. Hyman, Ahmet Zehir, Michael F. Berger, Benjamin D. Greenbaum and Sviatoslav M. Kendall and has published in prestigious journals such as Science, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Claud Grigg

19 papers receiving 1.5k citations

Hit Papers

Patient HLA class I genotype influences cancer response t... 2017 2026 2020 2023 2017 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
    2017 738 citations Diego Chowell, Luc G.T. Morris et al. Science profile →
  2. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
    2020 425 citations Catherine A. Shu, Justin F. Gainor et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Claud Grigg United States 9 1.2k 681 490 219 212 22 1.5k
Nathalie Rabbe France 20 1.1k 1.0× 589 0.9× 827 1.7× 325 1.5× 161 0.8× 27 1.7k
Lisa M. Cordes United States 20 1.2k 1.0× 412 0.6× 522 1.1× 308 1.4× 124 0.6× 105 1.6k
Mahrukh Huseni United States 12 1.1k 0.9× 562 0.8× 800 1.6× 336 1.5× 240 1.1× 30 1.6k
Jean-Marie Cuillerot United States 12 1.4k 1.2× 511 0.8× 683 1.4× 154 0.7× 90 0.4× 31 1.6k
Fernando Concha‐Benavente United States 19 1.1k 0.9× 281 0.4× 688 1.4× 267 1.2× 169 0.8× 31 1.4k
Christopher J. Nirschl United States 11 1.3k 1.1× 319 0.5× 1.0k 2.0× 245 1.1× 128 0.6× 31 1.7k
Karl Heath United States 9 1.3k 1.1× 453 0.7× 490 1.0× 309 1.4× 189 0.9× 14 1.6k
Max M. Wattenberg United States 14 843 0.7× 251 0.4× 505 1.0× 240 1.1× 250 1.2× 25 1.2k
Alison Klein United States 3 1.7k 1.4× 463 0.7× 843 1.7× 202 0.9× 196 0.9× 4 1.9k
James L. Reading United Kingdom 14 698 0.6× 272 0.4× 543 1.1× 391 1.8× 263 1.2× 29 1.4k

Countries citing papers authored by Claud Grigg

Since Specialization
Citations

This map shows the geographic impact of Claud Grigg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claud Grigg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claud Grigg more than expected).

Fields of papers citing papers by Claud Grigg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claud Grigg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claud Grigg. The network helps show where Claud Grigg may publish in the future.

Co-authorship network of co-authors of Claud Grigg

This figure shows the co-authorship network connecting the top 25 collaborators of Claud Grigg. A scholar is included among the top collaborators of Claud Grigg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claud Grigg. Claud Grigg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burgess, Earle F., Claud Grigg, Danielle Boselli, et al.. (2025). Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial. Clinical Genitourinary Cancer. 23(2). 102302–102302.
2.
Zhu, Jason, Chad Livasy, James T. Symanowski, et al.. (2023). Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer. Translational Andrology and Urology. 12(2). 228–240. 3 indexed citations
3.
Burgess, Earle F., Chad Livasy, James T. Symanowski, et al.. (2023). Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites. Urologic Oncology Seminars and Original Investigations. 41(8). 357.e23–357.e29. 1 indexed citations
4.
Grigg, Claud, Wei Sha, Landon C. Brown, et al.. (2023). Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). e16538–e16538.
5.
Burgess, Earle F., Joyce Sanders, Chad Livasy, et al.. (2022). Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes. Urologic Oncology Seminars and Original Investigations. 40(8). 383.e1–383.e10. 2 indexed citations
6.
Adeyemi, Oluwaseun, William E. Anderson, Timothy Hetherington, et al.. (2021). Racial Disparities in Prostate Specific Antigen Screening and Referral to Urology in a Large, Integrated Health Care System: A Retrospective Cohort Study. The Journal of Urology. 206(2). 270–278. 10 indexed citations
7.
Sanders, Joyce, Justin T. Matulay, Nury Steuerwald, et al.. (2021). Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients. Translational Andrology and Urology. 10(7). 2998–3009. 4 indexed citations
8.
Grigg, Claud, Sally J. Trufan, Peter E. Clark, et al.. (2021). Survival trends of men and women with metastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology. 39(15_suppl). 4566–4566. 1 indexed citations
9.
Grigg, Claud, Danielle Boselli, Chad Livasy, et al.. (2020). Limited Stage Small Cell Bladder Cancer: Outcomes of a Contemporary Cohort. Bladder Cancer. 6(1). 83–90. 2 indexed citations
10.
11.
Burgess, Earle F., Nury Steuerwald, James T. Symanowski, et al.. (2020). Pathogenic variants in PTEN to predict for increased risk of relapse and death in patients with limited stage small cell bladder cancer.. Journal of Clinical Oncology. 38(6_suppl). 526–526.
12.
Shu, Catherine A., Justin F. Gainor, Mark M. Awad, et al.. (2020). Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology. 21(6). 786–795. 425 indexed citations breakdown →
13.
Burgess, Earle F., Chad Livasy, Sally J. Trufan, et al.. (2019). High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urologic Oncology Seminars and Original Investigations. 37(12). 900–906. 5 indexed citations
14.
Burgess, Earle F., Chad Livasy, Myra Robinson, et al.. (2019). Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urologic Oncology Seminars and Original Investigations. 37(5). 299.e19–299.e25. 27 indexed citations
15.
Burgess, Earle F., Chad Livasy, Sally J. Trufan, et al.. (2019). Impact of Aurora kinase A and B expression on response to neoadjuvant chemotherapy and patient outcome in muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 37(7_suppl). 393–393. 2 indexed citations
16.
Shu, Catherine A., Claud Grigg, Codruța Chiuzan, et al.. (2018). Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). 8532–8532. 31 indexed citations
17.
Chowell, Diego, Luc G.T. Morris, Claud Grigg, et al.. (2017). Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 359(6375). 582–587. 738 indexed citations breakdown →
18.
Grigg, Claud, et al.. (2017). Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.. Journal of Clinical Oncology. 35(15_suppl). 9082–9082. 32 indexed citations
19.
Grigg, Claud, Zoë Blake, Robyn D. Gartrell, et al.. (2016). Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. Seminars in Oncology. 43(6). 638–646. 51 indexed citations
20.
Grigg, Claud & Naiyer A. Rizvi. (2016). PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. Journal for ImmunoTherapy of Cancer. 4(1). 48–48. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathalie Rabbe Breakdown of academic impact, for papers by Lisa M. Cordes Breakdown of academic impact, for papers by Mahrukh Huseni Breakdown of academic impact, for papers by Jean-Marie Cuillerot Breakdown of academic impact, for papers by Fernando Concha‐Benavente Breakdown of academic impact, for papers by Christopher J. Nirschl Breakdown of academic impact, for papers by Karl Heath Breakdown of academic impact, for papers by Max M. Wattenberg Breakdown of academic impact, for papers by Alison Klein Breakdown of academic impact, for papers by James L. Reading
Rankless by CCL
2026